← Back to all trials
Not Yet Recruiting
NCT05725070
Phase 0/1 Study of 212Pb-NG001 in mCRPC
Conditions: Metastatic Castration-resistant Prostate Cancer
Sex: Male
Ages: 18 Years – N/A
Phase: EARLY_PHASE1
Enrollment: 23
Sponsor: ARTBIO Inc.
Location: Norway
Summary
The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.
Eligibility Criteria
Key Inclusion Criteria:ECOG performance status of 0 to 2Life expectancy >6 monthsHistological, pathological, and/or cytological confirmation of prostate cancerMetastatic castration resistant prostate cancerFailure of conventional treatment or such treatment not available/accepted by patientPSMA avid mCRPC lesions confirmed by PSMA PET/CTAdequate hematopoietic, kidney and liver functionKey Exclusion Criteria:Concurrent or other cancer diagnosis last two years, except for carcinoma in situConcomitant diseases not compatible for radioactive therapyPrevious PSMA-targeted radioligand therapyConcurrent serious (as determined by the Principal Investigator) medical conditionsNote: Other protocol defined Inclusion/Exclusion criteria apply.
Source: ClinicalTrials.gov (NCT05725070). StuddyBuddy aggregates publicly available trial information.
